Table 3.
UTP modulates BON cells MP by fine tuning of a number of ionic conductances.
| Drug | Condition | Description | p-value | MP Depolarization (mV) | Increase in ICa2+ |
|---|---|---|---|---|---|
| UTP | 100 μM (3 min) | P2Y2,4,6 endogenous agonist | n/a | 5.94 ± 0.88 n = 17/34; (↑Ri) | p < 0.0001; n = 10 (Vm -20 to 40 mV) |
| UTPγS | 30 μM (3 min) | P2Y2,4 agonist | n/a | n/a | p < 0.0001; n = 6 (Vm -30 to 20 mV) |
| UDP | 100 μM (3 min) | P2Y6 agonist | P > 0.05 | n/a | ICa, p = NS; n = 8 Voltage dependence, p = 0.028; n = 8 (V50 -13.6 to -7.9) |
| Ca2+ free E.S. + EGTA | n/a | VOCa2+ channels inhibition | P > 0.05 | 4.66 ± 1.38, 3.70 ± 0.47 n = 9–10 | n/a |
| Lanthanum3+ | 100 μ (10 min) | VOCa2+ channels blocker | P > 0.05 | 6.90 ± 1.05, 4.93 ± 1.07 n = 8–11 | n/a |
| Thapsigargin | 1 μM (10 min) | SERCA inhibitor | P > 0.05 | 4.90 ± 1.14, 6.18 ± 1.29 n = 11 | n/a |
| U73122 vs. U73343 | 2.5 μM (5 min) | PLC antagonist | P < 0.05, χ2 | # cells: 0/8, 5/12 | n/a |
| GF109203X | 0.5 μM (10 min) | PKC α,βI,βII, δ and ε inhibitor | P > 0.05 | 6.00 ± 1.00, 7.66 ± 1.45 n = 3 | n/a |
| UTP vs. UTPγS | 30 μM (3 min) | P2Y2,4 agonist | P > 0.05 | 7.16 ± 1.74, 6.83 ± 2.08 n = 6; (↑Ri) | n/a |
| UTPγS, +UTP | 30 μM (3 min) | P2Y2,4 agonist | P < 0.05 | 8.30 ± 2.08, 0.40 ± 0.24 n = 5 | n/a |
| UTP vs. XE-991 | 10 μM (10 min) | Kv 7.1,7.2 and 7.3 (KCNQ) blocker | P > 0.05 | 5.13 ± 0.64, 6.08 ± 0.82 n = 8–12; (↑Ri) | n/a |
| UTP, +XE-991 | 10 μM (10 min) | Kv7.1,7.2 and 7.3 (KCNQ) blocker | P < 0.05, χ2 | # cells: 8/15, 2/17 | n/a |